Two recent regenerative studies report reproducible restoration of ovarian function after cyclophosphamide‑induced damage: one paper shows cell therapy using oxidoreductase mechanisms can stimulate ovarian rejuvenation, and a complementary study demonstrates mesenchymal stem cell‑derived extracellular vesicles reduce inflammation linked to ovarian aging. Researchers led by Zhang, Chen, and Yang tested cell therapies in preclinical models and documented functional improvements consistent with follicular rescue and hormonal recovery. Separate experiments with MSC‑derived vesicles showed anti‑inflammatory effects that preserved ovarian reserve markers. Both approaches use different modalities—whole cell therapy and acellular vesicles—but converge on restoring reproductive capacity after chemotherapy. Translational steps will include dose optimization, safety profiling and demonstration of sustained function in larger preclinical models before human trials.